Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-22 10:40:40 Source:travelViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:Singapore Airlines: 1 dead, others injured after London
Next:Trump says he is open to restrictions on contraception before backing away from the statement
You may also like
- Tigers starter Olson leaves game against Royals after being struck by line drive
- McDonald's is dishing out Chicken McNuggets at a discounted price
- I found BUGS wriggling in my Sainsbury's risotto rice
- Major NHS shake
- Weather forecasters warn Pakistanis to stay indoors ahead of new heat wave
- How Christopher Nolan couldn't have won his first Oscar without his family's support
- Hannah Elizabeth puts on a busty display in an off
- Sky is back online following a five
- New York's high court upholds requiring insurance to cover medically necessary abortions